Cite
MLA Citation
P. Ghia et al.. “P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP.” HemaSphere, vol. 6, n.d., pp. 566–567. http://access.bl.uk/ark:/81055/vdc_100159757189.0x00000f